Eugit Therapeutics is thrilled to announce that we have been awarded an NSF Phase 1 grant for our work on tissue targeting technology. This milestone wouldn't have been possible without the incredible support and collaboration of many individuals and organizations: - George Church, Nizar Batada, Yoshinori Fukazawa, Ernest F. Ribera, M.D. NAMITA ROUT -- thank you for your relentless dedication. - Our investors, including Y Combinator, Ethan Perlstein and Oleksiy Ignatyev, Ph.D. who believed in our vision. - To our friends, colleagues and mentors—Prof. Dietmar Zaiss, Stefan Symeonides, Mark Selby, Joe Collura, Douglas Crawford Lexi Rovner and many others -- your guidance has been invaluable. - A special thanks to the NSF and our Program Officer, Henry Ahn and the grant reviewers, for believing in our potential. - And last but not least, Ana Ortiz, PhD, for your exceptional support with the grant writeup.
Eugit Therapeutics
Biotechnology Research
San Carlos, California 848 followers
Tissue targeting of therapies
About us
Cofounded by George Church (Harvard) and funded by Y Combinator (S22) and NSF Ph1 grant (https://www.nsf.gov/awardsearch/showAward?AWD_ID=2423571&HistoricalAwards=false)
- Website
-
Www.eugittx.com
External link for Eugit Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- San Carlos, California
- Type
- Privately Held
- Founded
- 2022
- Specialties
- Immune system, Drug discovery, Immune-mediated diseases, Inflammatory Bowels Disease, IBD, and gamma delta T cells
Locations
-
Primary
Get directions
San Carlos, California , US